5 hours ago
Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415. The reason, as strange as it sounds, is a drug it does not own. Novartis announced that pelacarsen, an Lp(a)-lowering therapy, missed its Phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON. And since Amgen's late-stage ******* et olpasiran relies on the same biological premise, investors immediately marked down Amgen on the negative read-through.
The result strikes at a premise rather than at a product. Pelacarsenhad lowered Lp(a) by roughly 80% in earlier studies. In Lp(a)HORIZON, Novartis said pelacarsen substantially lowered Lp(a), but it still failed to reduce the composite of cardiovascular death, heart attack, stroke, and urgent revascularization. It still could not reduce the composite of cardiovascular death, heart attack, stroke, and urgent revascularization. And now the entire hypothesis that lowering Lp(a), a genetic cardiovascular risk factor, actually cuts events, is being directly challenged. Olpasiran is built on the same hypothesis, leading to the repricing of odds as soon as pelacarsen's data were out.
Amgen's olpasiran, an siRNA, lowered Lp(a) by more than 95% at certain doses in Phase 2, compared with reductions of roughly 80% for pelacarsen in earlier studies. The bull case is that this deeper reduction could help olpasiran deliver better cardiovascular outcomes.. The bull case is that this 15% will help Amgen to make a deeper cut and deliver results. While biologically possible, the Lp(a)HORIZON trial provided no evidence that a clinical threshold exists above an 80% reduction. The topline Phase 3 announcement did not establish that deeper Lp(a) lowering would have produced a cardiovascular benefit. It is therefore appropriate to say that the miss lowered olpasiran's probability of success rather than pretending it is irrelevant. Eli Lilly's lepodisiran is running the same deep-reduction experiment, so the hypothesis will be tested with or without Amgen.
Amgen is not an Lp(a) pure-play. MariTide in obesity, Repatha in cholesterol, and Tezspire in asthma drive more value for the company, and this diversification creates a cushion for the stock, although the selloff ultimately became much larger than the initial 5% after-hours reaction. Positioning has stayed calm since the beginning of 2026. Insider Monkey data shows 66 hedge funds held AMGN in the second quarter of 2026, up slightly from 65 in the first. Short interest, on the other hand, sits at just 2.4% of float, reflecting minimal bets against the stock in the market.
#horizon #pelacarsen
The result strikes at a premise rather than at a product. Pelacarsenhad lowered Lp(a) by roughly 80% in earlier studies. In Lp(a)HORIZON, Novartis said pelacarsen substantially lowered Lp(a), but it still failed to reduce the composite of cardiovascular death, heart attack, stroke, and urgent revascularization. It still could not reduce the composite of cardiovascular death, heart attack, stroke, and urgent revascularization. And now the entire hypothesis that lowering Lp(a), a genetic cardiovascular risk factor, actually cuts events, is being directly challenged. Olpasiran is built on the same hypothesis, leading to the repricing of odds as soon as pelacarsen's data were out.
Amgen's olpasiran, an siRNA, lowered Lp(a) by more than 95% at certain doses in Phase 2, compared with reductions of roughly 80% for pelacarsen in earlier studies. The bull case is that this deeper reduction could help olpasiran deliver better cardiovascular outcomes.. The bull case is that this 15% will help Amgen to make a deeper cut and deliver results. While biologically possible, the Lp(a)HORIZON trial provided no evidence that a clinical threshold exists above an 80% reduction. The topline Phase 3 announcement did not establish that deeper Lp(a) lowering would have produced a cardiovascular benefit. It is therefore appropriate to say that the miss lowered olpasiran's probability of success rather than pretending it is irrelevant. Eli Lilly's lepodisiran is running the same deep-reduction experiment, so the hypothesis will be tested with or without Amgen.
Amgen is not an Lp(a) pure-play. MariTide in obesity, Repatha in cholesterol, and Tezspire in asthma drive more value for the company, and this diversification creates a cushion for the stock, although the selloff ultimately became much larger than the initial 5% after-hours reaction. Positioning has stayed calm since the beginning of 2026. Insider Monkey data shows 66 hedge funds held AMGN in the second quarter of 2026, up slightly from 65 in the first. Short interest, on the other hand, sits at just 2.4% of float, reflecting minimal bets against the stock in the market.
#horizon #pelacarsen
5 hours ago
The stars will be in Surrey (England) this week as an absolutely stacked field competes at the BMW PGA Championship.
144 players will tee off at Wentworth Club this week looking for a piece of the $9 million purse at stake on the DP World Tour.
The high-powered field includes, Rory McIlroy, Shane Lowry fresh off his Amgen Irish Open victory, Brooks Koepka, Alex and Matt Fitzpatrick, Patrick Reed, Ryan Fox, Aaron Rai, Tommy Fleetwood and defending champ Alex Noren. And, that's just the list we could fit on two hands.
Here's how you can watch the BMW PGA Championship on Golf Channel and Golf Channel mobile (ET):
Thursday, Sept. 17:
#alex #field #england
144 players will tee off at Wentworth Club this week looking for a piece of the $9 million purse at stake on the DP World Tour.
The high-powered field includes, Rory McIlroy, Shane Lowry fresh off his Amgen Irish Open victory, Brooks Koepka, Alex and Matt Fitzpatrick, Patrick Reed, Ryan Fox, Aaron Rai, Tommy Fleetwood and defending champ Alex Noren. And, that's just the list we could fit on two hands.
Here's how you can watch the BMW PGA Championship on Golf Channel and Golf Channel mobile (ET):
Thursday, Sept. 17:
#alex #field #england
3 days ago
The Amgen Irish Open at Trump International Doonbeg has turned into a story of resilience and record-breaking golf. While the first round saw players battling wind and rain that made the course play brutally difficult, the second round brought a dramatic shift in fortune. Shane Lowry, the local favorite, didn't just survive the conditions; he absolutely dominated them. After airing his frustration with the slow pace caused by the weather in the opening round, Lowry produced a stunning performance to take the lead. Golf Monthly reports that Lowry shot a record-breaking 62 under much kinder conditions to take the lead at the midpoint. This score puts him two shots clear of the field and sets the stage for a thrilling weekend.
The contrast between the two rounds couldn't be starker. The first day was defined by struggle, with Golf Monthly noting that the brutal conditions contributed to slow play across the property. Players like Lowry had to wait for groups ahead, testing their patience. Yet, when the wind died down, Lowry found his rhythm. He isn't alone in the hunt, however. The chasing pack is packed with talent, including defending champion Rory McIlroy, two-time Major winner Jon Rahm, and Brooks Koepka, all of whom Golf Monthly confirmed will join Lowry in the third round. Joaquin Niemann, the first-round leader, also remains in contention to challenge the Irishman.
While Lowry's score grabs the headlines, the most compelling story of the week might be the rise of Niklas Nørgaard. The Danish golfer has moved into a tie for second place alongside Jacob Skov Olesen and Haotong Li after posting matching 64s, according to europeantour.com. This surge came from a fundamental change in how Nørgaard approached the game, not just better ball-striking. The pressure of competition often weighs heavy, but Nørgaard found a way to lighten the load. A shift in mindset this week earned praise for his caddie, as he disclosed that his coach is actually riding in the bag during this event.
Nørgaard explained his strategy directly to the media, and the result was immediate. Europeantour.com notes that Nørgaard received late applause from spectators after draining a vital putt on the 18th and finishing his round with a closing birdie to enter the chase. His back nine was a blur of birdies, specifically a burst from the 14th to 16th holes that propelled him up the leaderboard. You have to wonder if that mental shift is the only thing standing between him and a ***** le run, considering how tight the field really is.
Other players faced different challenges. Thomas Detry made an albatross at the par-5 10th in the opening round, a rare feat that should have boosted his day. However, he finished the first day with a 74 and ultimately missed the cut, according to Golf Monthly. On the other side of the field, David Puig struggled to find consistency. Following a 71 in the opening round that left him one over par, he posted the exact same score during the second rou
The contrast between the two rounds couldn't be starker. The first day was defined by struggle, with Golf Monthly noting that the brutal conditions contributed to slow play across the property. Players like Lowry had to wait for groups ahead, testing their patience. Yet, when the wind died down, Lowry found his rhythm. He isn't alone in the hunt, however. The chasing pack is packed with talent, including defending champion Rory McIlroy, two-time Major winner Jon Rahm, and Brooks Koepka, all of whom Golf Monthly confirmed will join Lowry in the third round. Joaquin Niemann, the first-round leader, also remains in contention to challenge the Irishman.
While Lowry's score grabs the headlines, the most compelling story of the week might be the rise of Niklas Nørgaard. The Danish golfer has moved into a tie for second place alongside Jacob Skov Olesen and Haotong Li after posting matching 64s, according to europeantour.com. This surge came from a fundamental change in how Nørgaard approached the game, not just better ball-striking. The pressure of competition often weighs heavy, but Nørgaard found a way to lighten the load. A shift in mindset this week earned praise for his caddie, as he disclosed that his coach is actually riding in the bag during this event.
Nørgaard explained his strategy directly to the media, and the result was immediate. Europeantour.com notes that Nørgaard received late applause from spectators after draining a vital putt on the 18th and finishing his round with a closing birdie to enter the chase. His back nine was a blur of birdies, specifically a burst from the 14th to 16th holes that propelled him up the leaderboard. You have to wonder if that mental shift is the only thing standing between him and a ***** le run, considering how tight the field really is.
Other players faced different challenges. Thomas Detry made an albatross at the par-5 10th in the opening round, a rare feat that should have boosted his day. However, he finished the first day with a 74 and ultimately missed the cut, according to Golf Monthly. On the other side of the field, David Puig struggled to find consistency. Following a 71 in the opening round that left him one over par, he posted the exact same score during the second rou
4 days ago
On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints at week 24 in patients with eosinophilic esophagitis. These benefits were sustained through week 52 across both tested doses, accompanied by a safety profile consistent with its approved indications. While CROSSING highlights their joint R&D success, a closer look at their standalone financial performance reveals distinct growth trajectories.
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC (NYSE:AZN)'s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. (NASDAQ:AMGN) reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN's mature products.
Amgen's bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline ****** ets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
#revenue #astrazeneca #increased #products
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC (NYSE:AZN)'s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. (NASDAQ:AMGN) reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN's mature products.
Amgen's bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline ****** ets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
#revenue #astrazeneca #increased #products
7 days ago
The Dow Jones Industrial Average and the other major stock indexes fell Tuesday, with oil prices rising following an attack on Saudi Arabia by Iran-backed Houthis. Energy stocks jumped while software lagged. Meanwhile, memory-chip leader SK Hynix (SKHY) rallied on the stock market today, breaking out past a new buy point.
Stocks were under pressure in the first day of the shortened trading week, with the Dow industrials diving nearly 700 points. This equates to a 1.3% drop. Oil major Chevron (CVX) stood out with a 2% pop, putting shares back in a buy zone.
But Amgen (AMGN) plunged 9% and dropped to its 50-day moving average. It comes after a disappointing trial results for an experimental Novartis (NVS) cardiovascular treatment were seen as a negative indicator for the former firm's own fledgling heart treatment olpasiran. Novartis, not a blue chip stock, plummeted more than 13%.
The S&P 500 also felt the heat, dropping 0.4%. A majority of sectors were lower, with communication services and healthcare being hit the hardest. Energy and utilities were posting the best gains.
The tech-heavy Nasdaq composite was also being punished, falling 0.5%. Booking (BKNG) and Shopify (SHOP) lagged due to drops of more than 5% and around 8%, respectively. CoreWeave (CRWV) showed strength by rising more than 8%.
#major #rising #lagged
Stocks were under pressure in the first day of the shortened trading week, with the Dow industrials diving nearly 700 points. This equates to a 1.3% drop. Oil major Chevron (CVX) stood out with a 2% pop, putting shares back in a buy zone.
But Amgen (AMGN) plunged 9% and dropped to its 50-day moving average. It comes after a disappointing trial results for an experimental Novartis (NVS) cardiovascular treatment were seen as a negative indicator for the former firm's own fledgling heart treatment olpasiran. Novartis, not a blue chip stock, plummeted more than 13%.
The S&P 500 also felt the heat, dropping 0.4%. A majority of sectors were lower, with communication services and healthcare being hit the hardest. Energy and utilities were posting the best gains.
The tech-heavy Nasdaq composite was also being punished, falling 0.5%. Booking (BKNG) and Shopify (SHOP) lagged due to drops of more than 5% and around 8%, respectively. CoreWeave (CRWV) showed strength by rising more than 8%.
#major #rising #lagged
28 days ago
Fanatics is turning its gaze overseas.
The digital sports platform and licensed sports merchandiser has signed a multiyear partnership with the European Tour Group to become the exclusive operator of the official DP World Tour and the Ryder Cup European store. It will also become the exclusive retail partner for the 2027 Ryder Cup at Adare Manor in Limerick, Ireland, as well as the Amgen Irish Open, Genesis Scottish Open, BMW PGA Championship and Husqvarna British.
More from WWD
LoveShackFancy, Fanatics Team on Limited-edition College Collection
Centric Creates Joint Venture With Eastside Golf
#fanatics #become #World
The digital sports platform and licensed sports merchandiser has signed a multiyear partnership with the European Tour Group to become the exclusive operator of the official DP World Tour and the Ryder Cup European store. It will also become the exclusive retail partner for the 2027 Ryder Cup at Adare Manor in Limerick, Ireland, as well as the Amgen Irish Open, Genesis Scottish Open, BMW PGA Championship and Husqvarna British.
More from WWD
LoveShackFancy, Fanatics Team on Limited-edition College Collection
Centric Creates Joint Venture With Eastside Golf
#fanatics #become #World
1 month ago
During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology ***** e. He said:
Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the… Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these… I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on any weakness.
Cramer's thesis highlights how mega-cap healthcare operators provide defensive shelter with strong dividend profiles and maintain high-growth product pipelines. Cramer further emphasized that innovation in biotechnology is driving tangible financial gains. He said:
Amgen just racked up an excellent quarter. And credit where credit's due, time to accept that Moderna has begun to realize its stream of specialized vaccines for specific illnesses. Just last night, the company, it received FDA approval for its mRNA flu vaccine. Well, there's a reason why the stock's up 83% for the year.
Later in the August 6 episode, a caller asked Cramer about Bristol-Myers Squibb Company (NYSE:BMY) after holding the stock through recent buyout speculation. In response, Cramer remarked:
#episode #managers
Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the… Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these… I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on any weakness.
Cramer's thesis highlights how mega-cap healthcare operators provide defensive shelter with strong dividend profiles and maintain high-growth product pipelines. Cramer further emphasized that innovation in biotechnology is driving tangible financial gains. He said:
Amgen just racked up an excellent quarter. And credit where credit's due, time to accept that Moderna has begun to realize its stream of specialized vaccines for specific illnesses. Just last night, the company, it received FDA approval for its mRNA flu vaccine. Well, there's a reason why the stock's up 83% for the year.
Later in the August 6 episode, a caller asked Cramer about Bristol-Myers Squibb Company (NYSE:BMY) after holding the stock through recent buyout speculation. In response, Cramer remarked:
#episode #managers
1 month ago
The S&P 500 Index ($SPX) (SPY) today is up +0.31%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.05%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.03%. September E-mini S&P futures (ESU26) are up +0.33%, and September E-mini Nasdaq futures (NQU26) are down -0.02%.
Stock indices are trading mixed today, with the S&P 500 and Dow Jones Industrials posting new all-time highs. Some positive corporate earnings results are supporting gains in stock indices today. Booking Holdings is up more than +7% after reporting better-than-expected Q2 gross bookings. Also, Amgen is up more than +5% after reporting stronger-than-expected Q2 EPS.
Jeff Bezos Says He's Selling $1 Billion In Amazon Stock Every Year to Fund Blue Origin — 'It's The Most Important Work I'm Doing'
Apple's New CEO Is Bringing a Familiar Face Back From Retirement. The Shift Is Happening.
Nasdaq Futures Climb as Tech Rally Continues on Palantir Boost, U.S. JOLTS Report and ****** eX Earnings on Tap
#futures #today #earnings #down
Stock indices are trading mixed today, with the S&P 500 and Dow Jones Industrials posting new all-time highs. Some positive corporate earnings results are supporting gains in stock indices today. Booking Holdings is up more than +7% after reporting better-than-expected Q2 gross bookings. Also, Amgen is up more than +5% after reporting stronger-than-expected Q2 EPS.
Jeff Bezos Says He's Selling $1 Billion In Amazon Stock Every Year to Fund Blue Origin — 'It's The Most Important Work I'm Doing'
Apple's New CEO Is Bringing a Familiar Face Back From Retirement. The Shift Is Happening.
Nasdaq Futures Climb as Tech Rally Continues on Palantir Boost, U.S. JOLTS Report and ****** eX Earnings on Tap
#futures #today #earnings #down
1 month ago
Amgen reported second-quarter results on Tuesday that topped expectations, raised its full-year outlook, and disclosed it was ending development of an early-stage weight loss drug candidate.
The Thousand Oaks, California-based biotech earned $2.38 billion in the second quarter, translating to $4.37 per diluted share, a significant jump from the $1.43 billion, or $2.65 per share, it recorded in the year-ago period. On an adjusted basis, earnings came to $6.29 per share, up 4% year over year. **** ysts had expected adjusted earnings of $5.62 per share, according to the Wall Street Journal.
Total revenue climbed 10% to $10.05 billion, compared with $9.18 billion in the second quarter of 2025, the company said. Product sales grew 9% to $9.54 billion, driven by volume growth. **** ysts had expected revenue of $9.43 billion, according to the Journal.
Among the top performers, cholesterol drug Repatha posted sales of $953 million, up 37% year over year, while bone drug Evenity generated $714 million, up 38%. Rare disease treatment Uplizna grew 90% to $335 million. Cancer drug Imdelltra rose 115% to $288 million.
Amgen lifted its full-year 2026 guidance, now targeting total revenue in a range of $38.2 billion to $39.4 billion, which compares favorably to its previous forecast of $37.1 billion to $38.5 billion. On the earnings side, the company set an adjusted EPS target of $22.30 to $23.50, stepping up from its prior range of $21.70 to $23.10.
#billion #drug #million #quarter
The Thousand Oaks, California-based biotech earned $2.38 billion in the second quarter, translating to $4.37 per diluted share, a significant jump from the $1.43 billion, or $2.65 per share, it recorded in the year-ago period. On an adjusted basis, earnings came to $6.29 per share, up 4% year over year. **** ysts had expected adjusted earnings of $5.62 per share, according to the Wall Street Journal.
Total revenue climbed 10% to $10.05 billion, compared with $9.18 billion in the second quarter of 2025, the company said. Product sales grew 9% to $9.54 billion, driven by volume growth. **** ysts had expected revenue of $9.43 billion, according to the Journal.
Among the top performers, cholesterol drug Repatha posted sales of $953 million, up 37% year over year, while bone drug Evenity generated $714 million, up 38%. Rare disease treatment Uplizna grew 90% to $335 million. Cancer drug Imdelltra rose 115% to $288 million.
Amgen lifted its full-year 2026 guidance, now targeting total revenue in a range of $38.2 billion to $39.4 billion, which compares favorably to its previous forecast of $37.1 billion to $38.5 billion. On the earnings side, the company set an adjusted EPS target of $22.30 to $23.50, stepping up from its prior range of $21.70 to $23.10.
#billion #drug #million #quarter
2 months ago
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Sarepta Therapeutics has found the leader it hopes can engineer a desperately needed turnaround.
The company on Monday announced that Michael Severino, an executive with leadership experience at startups as well as large drugmakers, will become its next CEO effective July 28. He'll replace longtime leader Doug Ingram, who in February announced plans to retire after a tumultuous run.
Severino has been working in the biopharmaceutical industry for more than two decades, including stops at AbbVie and Amgen. At AbbVie, Severino helped bring to market multiple drugs for psoriasis, arthritis, cancer and hepatitis C. At Amgen, he oversaw research and development as the company's senior vice president of development and corporate chief medical officer.
In 2022, Severino left AbbVie to run Tessera Therapeutics, a buzzy "gene writing" startup backed by Flagship Pioneering. Tessera recently brought its first drug prospect, a gene editing treatment for alpha-1 antitrypsin deficiency, into clinical testing. Last week, Tessera announced that Severino had joined a "commercial stage" biotech company and that former Merck & Co. executive Joseph Romanelli would serve as its next leader.
#abbvie #tessera #biopharma #amgen
Sarepta Therapeutics has found the leader it hopes can engineer a desperately needed turnaround.
The company on Monday announced that Michael Severino, an executive with leadership experience at startups as well as large drugmakers, will become its next CEO effective July 28. He'll replace longtime leader Doug Ingram, who in February announced plans to retire after a tumultuous run.
Severino has been working in the biopharmaceutical industry for more than two decades, including stops at AbbVie and Amgen. At AbbVie, Severino helped bring to market multiple drugs for psoriasis, arthritis, cancer and hepatitis C. At Amgen, he oversaw research and development as the company's senior vice president of development and corporate chief medical officer.
In 2022, Severino left AbbVie to run Tessera Therapeutics, a buzzy "gene writing" startup backed by Flagship Pioneering. Tessera recently brought its first drug prospect, a gene editing treatment for alpha-1 antitrypsin deficiency, into clinical testing. Last week, Tessera announced that Severino had joined a "commercial stage" biotech company and that former Merck & Co. executive Joseph Romanelli would serve as its next leader.
#abbvie #tessera #biopharma #amgen
2 months ago
Thousand Oaks, California-based Amgen Inc. (AMGN) is a leading independent biotechnology company that discovers, develops, manufactures, and delivers innovative biologic medicines for serious diseases. With a market capitalization of approximately $197.7 billion, the company focuses on oncology, inflammation, general medicine, and rare diseases, leveraging advanced human genetics and biologics manufacturing to improve patient outcomes globally.
AMGN is set to report its Q2 earnings on Wednesday, August 5, 2026, after the market closes. Ahead of the release, ***** ysts expect the company to report a diluted EPS of $5.57, down 7.5% from $6.02 in the year-ago quarter. AMGN has exceeded Wall Street's EPS estimates in each of the past four trailing quarters, which is impressive.
Alibaba Stock Just Got Apple's Biggest AI Endorsement. This Could Be a Game Changer for BABA.
Elon Musk Says If ***** eX Accomplishes Its Goals, 'It Will Be Worth More Than The Rest of Earth' — Though He's Also Said 'Money Will Stop Being Relevant'
AI Bubble Fears, Earnings and Other Can't Miss Items this Week
#company
AMGN is set to report its Q2 earnings on Wednesday, August 5, 2026, after the market closes. Ahead of the release, ***** ysts expect the company to report a diluted EPS of $5.57, down 7.5% from $6.02 in the year-ago quarter. AMGN has exceeded Wall Street's EPS estimates in each of the past four trailing quarters, which is impressive.
Alibaba Stock Just Got Apple's Biggest AI Endorsement. This Could Be a Game Changer for BABA.
Elon Musk Says If ***** eX Accomplishes Its Goals, 'It Will Be Worth More Than The Rest of Earth' — Though He's Also Said 'Money Will Stop Being Relevant'
AI Bubble Fears, Earnings and Other Can't Miss Items this Week
#company
2 months ago
Amgen Inc. (NASDAQ:AMGN) ranks among the top NASDAQ stocks for retirement. On June 16, Mizuho increased its price target for Amgen Inc. (NASDAQ:AMGN) to $303 from $295 while keeping a Neutral rating on the company's shares, with the firm highlighting MariTide and olpasiran as crucial focal points for the company.
Mizuho said that Novartis and Ionis Pharmaceuticals' pelacarsen Phase 3 Lp(a) research is slated to conclude in the early second half of 2026, which might possibly ***** ist Amgen Inc. (NASDAQ:AMGN).
Mizuho slightly increased its medium-term sales outlook for Amgen Inc. (NASDAQ:AMGN), leading to a minor price target revision. As information from the Novartis and Ionis Phase 3 Lp(a) research becomes available, likely in the first half of 2026, the firm anticipates that market focus will turn toward olpasiran. The olpasiran data is expected to be released at a later time.
Meanwhile, Mizuho noted a potential risk ***** ociated with a tax dispute resolution projected no sooner than the latter half of 2026. The firm stated that it is seeking more details on the IRS tax dispute, which, as per Amgen's 10-Q filing, will not be resolved before the latter half of 2026.
Amgen Inc. (NASDAQ:AMGN) is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.
Mizuho said that Novartis and Ionis Pharmaceuticals' pelacarsen Phase 3 Lp(a) research is slated to conclude in the early second half of 2026, which might possibly ***** ist Amgen Inc. (NASDAQ:AMGN).
Mizuho slightly increased its medium-term sales outlook for Amgen Inc. (NASDAQ:AMGN), leading to a minor price target revision. As information from the Novartis and Ionis Phase 3 Lp(a) research becomes available, likely in the first half of 2026, the firm anticipates that market focus will turn toward olpasiran. The olpasiran data is expected to be released at a later time.
Meanwhile, Mizuho noted a potential risk ***** ociated with a tax dispute resolution projected no sooner than the latter half of 2026. The firm stated that it is seeking more details on the IRS tax dispute, which, as per Amgen's 10-Q filing, will not be resolved before the latter half of 2026.
Amgen Inc. (NASDAQ:AMGN) is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.
3 months ago
Bank of America, UBS and Jefferies on Monday initiated coverage of quantum computing company Quantinuum (QNT) with buy ratings, touting its broad hardware and software platform. Quantinuum stock climbed on the news.
At Bank of America, ***** yst Vivek Arya initiated coverage of Quantinuum with a price target of 100.
"Quantinuum's newest platform, Helios, delivers industry-leading commercial performance and has already won over customers including Amgen and BMW who use it in the cloud and on premises," Arya said in a report. "While many quantum roadmaps rely on unproven integration and/or scientific progress, we think QNT's is relatively derisked, with scaling more dependent on engineering execution across its architecture and systems."
Jefferies ***** yst Kevin Garrigan set a price target of 90 on QNT stock. Controlled by Honeywell International (HON), Quantinuum launched an initial public offering on June 4.
"Quantinuum is a leading quantum computing company, differentiated by a vertically integrated full-stack model combining high-fidelity trapped-ion hardware, an industry-leading software stack, and a deep commercial customer base across chemistry, materials, financial services and cybersecurity," Garrigan said in a report.
At Bank of America, ***** yst Vivek Arya initiated coverage of Quantinuum with a price target of 100.
"Quantinuum's newest platform, Helios, delivers industry-leading commercial performance and has already won over customers including Amgen and BMW who use it in the cloud and on premises," Arya said in a report. "While many quantum roadmaps rely on unproven integration and/or scientific progress, we think QNT's is relatively derisked, with scaling more dependent on engineering execution across its architecture and systems."
Jefferies ***** yst Kevin Garrigan set a price target of 90 on QNT stock. Controlled by Honeywell International (HON), Quantinuum launched an initial public offering on June 4.
"Quantinuum is a leading quantum computing company, differentiated by a vertically integrated full-stack model combining high-fidelity trapped-ion hardware, an industry-leading software stack, and a deep commercial customer base across chemistry, materials, financial services and cybersecurity," Garrigan said in a report.
3 months ago
On June 23, S&P Dow Jones Indices announced that Alphabet would be replacing Verizon Communications in the Dow Jones Industrial Average.
Since 2020, seven of the Dow's 30 components have changed, including the additions of Honeywell International, Salesforce, Amgen, Amazon, Nvidia, Sherwin-Williams, and now Alphabet, and the deletions of RTX, ExxonMobil, Pfizer, Walgreens Boots Alliance, Intel, Dow, and Verizon.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Space Exploration Technologies (NASDAQ: SPCX) -- otherwise known as **** eX -- has only been public for a couple of weeks. But the company has a strong case for joining the Dow one day. Here are three reasons **** eX could eventually join the Dow, and whether the growth stock is a buy now.
With just 30 components, each Dow stock represents certain industries and a stock market sector. The strongest case for **** eX joining the Dow is that it is the undisputed leader in the commercial **** e launch industry -- conducting 82% of U.S. **** e launches.
Since 2020, seven of the Dow's 30 components have changed, including the additions of Honeywell International, Salesforce, Amgen, Amazon, Nvidia, Sherwin-Williams, and now Alphabet, and the deletions of RTX, ExxonMobil, Pfizer, Walgreens Boots Alliance, Intel, Dow, and Verizon.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Space Exploration Technologies (NASDAQ: SPCX) -- otherwise known as **** eX -- has only been public for a couple of weeks. But the company has a strong case for joining the Dow one day. Here are three reasons **** eX could eventually join the Dow, and whether the growth stock is a buy now.
With just 30 components, each Dow stock represents certain industries and a stock market sector. The strongest case for **** eX joining the Dow is that it is the undisputed leader in the commercial **** e launch industry -- conducting 82% of U.S. **** e launches.
3 months ago
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Amgen Inc. (NASDAQ:AMGN) is one of the best weight loss drugs on this list.
TheFly reported on June 16 that Mizuho ****** yst Salim Syed increased the price target for AMGN to $303 from $295 while maintaining a Neutral rating on the shares. The adjustment followed an update to the firm's valuation model after reviewing AMGN's first quarter results.
In separate news, on June 7, Amgen Inc. (NASDAQ:AMGN) presented new clinical findings at the American Diabetes ****** ociation (ADA) 86th Scientific Sessions, highlighting its efforts to address cardiovascular risks among people with cardiometabolic conditions. The company shared Phase 3 VESALIUS-CV subgroup data evaluating Repatha in 6,002 high-risk diabetes patients with elevated LDL-C levels who had not previously experienced a heart attack or stroke.
The ****** ysis showed that Repatha, used alongside statins or other LDL-C-lowering treatments, lowered the likelihood of major cardiovascular events, including coronary heart disease death, heart attack, or ischemic stroke, by 29% compared with placebo. The treatment also demonstrated a 21% reduction in a broader cardiovascular outcome that included ischemia-related revascularization. Patients receiving Repatha achieved a median LDL-C level of 45 mg/dL, compared with 106 mg/dL among those receiving placebo.
Amgen Inc. (NASDAQ:AMGN) is a global biotech company gaining investor attention in the weight-loss market through MariTide, an experimental obesity drug in Phase 3 trials. With potential monthly dosing and strong weight-loss results, MariTide could become a major competitor in the growing obesity treatment ****** e.
TheFly reported on June 16 that Mizuho ****** yst Salim Syed increased the price target for AMGN to $303 from $295 while maintaining a Neutral rating on the shares. The adjustment followed an update to the firm's valuation model after reviewing AMGN's first quarter results.
In separate news, on June 7, Amgen Inc. (NASDAQ:AMGN) presented new clinical findings at the American Diabetes ****** ociation (ADA) 86th Scientific Sessions, highlighting its efforts to address cardiovascular risks among people with cardiometabolic conditions. The company shared Phase 3 VESALIUS-CV subgroup data evaluating Repatha in 6,002 high-risk diabetes patients with elevated LDL-C levels who had not previously experienced a heart attack or stroke.
The ****** ysis showed that Repatha, used alongside statins or other LDL-C-lowering treatments, lowered the likelihood of major cardiovascular events, including coronary heart disease death, heart attack, or ischemic stroke, by 29% compared with placebo. The treatment also demonstrated a 21% reduction in a broader cardiovascular outcome that included ischemia-related revascularization. Patients receiving Repatha achieved a median LDL-C level of 45 mg/dL, compared with 106 mg/dL among those receiving placebo.
Amgen Inc. (NASDAQ:AMGN) is a global biotech company gaining investor attention in the weight-loss market through MariTide, an experimental obesity drug in Phase 3 trials. With potential monthly dosing and strong weight-loss results, MariTide could become a major competitor in the growing obesity treatment ****** e.
3 months ago
Amgen Inc. (NASDAQ:AMGN) is one of the
7 Best Longevity Stocks to Buy Now.
On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) announced new data at the American Diabetes ****** ociation 86th Scientific Sessions, including Phase 3 VESALIUS-CV subgroup results for Repatha in patients with high-risk diabetes and elevated LDL-C without prior heart attack or stroke. In an ****** ysis of 6,002 patients, Repatha, when added to statins or other LDL-C-lowering therapies, reduced the risk of the composite primary endpoint of coronary heart disease death, myocardial infarction, or ischemic stroke by 29% compared with placebo. Repatha also reduced the risk of a second composite primary endpoint that included ischemia-driven revascularization by 21%.
On June 5, 2026, Goldman Sachs lowered the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $389 from $425 and maintained a Buy rating on the shares. Goldman Sachs adjusted its model after Amgen disclosed in its Q1 earnings that the IRS audit for 2016 to 2018 had escalated into a formal dispute, with the company receiving a notice of proposed adjustment.
Earlier in June, Amgen announced that the European Commission granted marketing authorization for Imdylltra as a monotherapy for adults with extensive-stage small cell lung cancer who require systemic therapy after disease progression on or after first-line platinum-based chemotherapy.
7 Best Longevity Stocks to Buy Now.
On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) announced new data at the American Diabetes ****** ociation 86th Scientific Sessions, including Phase 3 VESALIUS-CV subgroup results for Repatha in patients with high-risk diabetes and elevated LDL-C without prior heart attack or stroke. In an ****** ysis of 6,002 patients, Repatha, when added to statins or other LDL-C-lowering therapies, reduced the risk of the composite primary endpoint of coronary heart disease death, myocardial infarction, or ischemic stroke by 29% compared with placebo. Repatha also reduced the risk of a second composite primary endpoint that included ischemia-driven revascularization by 21%.
On June 5, 2026, Goldman Sachs lowered the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $389 from $425 and maintained a Buy rating on the shares. Goldman Sachs adjusted its model after Amgen disclosed in its Q1 earnings that the IRS audit for 2016 to 2018 had escalated into a formal dispute, with the company receiving a notice of proposed adjustment.
Earlier in June, Amgen announced that the European Commission granted marketing authorization for Imdylltra as a monotherapy for adults with extensive-stage small cell lung cancer who require systemic therapy after disease progression on or after first-line platinum-based chemotherapy.
3 months ago
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. TScan Therapeutics, Inc. (NASDAQ:TCRX) is one of the most popular penny stocks.
TheFly reported on May 6 that TCRX announced its first-quarter 2026 financial results, covering the period ended March 31, 2026, along with a corporate update. The company reported revenue of $1.0 million versus $2.2 million in the prior-year quarter, reflecting lower research activity tied to its collaboration with Amgen. Research and development expenses totaled $21.9 million compared to $29.8 million a year earlier, while general and administrative expenses were $8.2 million versus $8.6 million, driven mainly by reduced professional costs and timing of spending.
The corporation’s net loss improved to $28.7 million from $34.1 million, supported by $0.5 million in net interest income compared with $2.1 million previously. Cash and cash equivalents stood at $128.1 million as of March 31, 2026, excluding $5.0 million restricted cash, with a runway expected into the second half of 2027. The update also outlined pipeline progress across heme malignancies, solid tumors, and autoimmune programs, including upcoming clinical milestones and preclinical developments.
In separate news, on April 27, TScan Therapeutics, Inc. (NASDAQ:TCRX) announced acceptance of a scientific abstract for presentation at the ASGCT 29th Annual Meeting in Boston, held May 11–15, 2026. The poster focuses on CD45-targeted TCR-T therapies aimed at eliminating residual disease and reducing relapse risk after allogeneic stem cell transplantation.
TScan Therapeutics, Inc. (NASDAQ:TCRX) is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered therapies for cancer and autoimmune diseases. It uses a proprietary platform to identify immune targets and design treatments that activate the body’s own T cells to fight disease.
TheFly reported on May 6 that TCRX announced its first-quarter 2026 financial results, covering the period ended March 31, 2026, along with a corporate update. The company reported revenue of $1.0 million versus $2.2 million in the prior-year quarter, reflecting lower research activity tied to its collaboration with Amgen. Research and development expenses totaled $21.9 million compared to $29.8 million a year earlier, while general and administrative expenses were $8.2 million versus $8.6 million, driven mainly by reduced professional costs and timing of spending.
The corporation’s net loss improved to $28.7 million from $34.1 million, supported by $0.5 million in net interest income compared with $2.1 million previously. Cash and cash equivalents stood at $128.1 million as of March 31, 2026, excluding $5.0 million restricted cash, with a runway expected into the second half of 2027. The update also outlined pipeline progress across heme malignancies, solid tumors, and autoimmune programs, including upcoming clinical milestones and preclinical developments.
In separate news, on April 27, TScan Therapeutics, Inc. (NASDAQ:TCRX) announced acceptance of a scientific abstract for presentation at the ASGCT 29th Annual Meeting in Boston, held May 11–15, 2026. The poster focuses on CD45-targeted TCR-T therapies aimed at eliminating residual disease and reducing relapse risk after allogeneic stem cell transplantation.
TScan Therapeutics, Inc. (NASDAQ:TCRX) is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered therapies for cancer and autoimmune diseases. It uses a proprietary platform to identify immune targets and design treatments that activate the body’s own T cells to fight disease.
